Beta-thalassemia natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
| Line 29: | Line 29: | ||
The prognosis of beta-thalassemia can also be influenced by [[cardiovascular]] involvement. | The prognosis of beta-thalassemia can also be influenced by [[cardiovascular]] involvement. | ||
* Parenchymal injury secondary to myocardial iron deposition and immune-inflammatory processes are known to be primary reasons for cardiovascular disorders in patients with thalassemia. | * [[Parenchymal]] injury secondary to myocardial iron deposition and immune-inflammatory processes are known to be primary reasons for [[cardiovascular]] disorders in patients with thalassemia. | ||
* Early abnormalities in ventricular myocardium can occur in patients with beta-thalassemia, even in those receiving effective chelation therapies. | * Early abnormalities in [[ventricular]] myocardium can occur in patients with [[beta-thalassemia]], even in those receiving effective [[chelation]] therapies. | ||
* Aortic elasticity indices are impaired in patients with beta-thalassemia major, and these parameters may be used to predict cardiovascular complications in asymptomatic patients<ref name="pmid26346439">{{cite journal |vauthors=Sahin C, Basaran O, Altun I, Akin F, Topal Y, Topal H, Biteker M, Azik MF |title=Assessment of Myocardial Performance Index and Aortic Elasticity in Patients With Beta-Thalassemia Major |journal=J Clin Med Res |volume=7 |issue=10 |pages=795–801 |date=October 2015 |pmid=26346439 |pmc=4554220 |doi=10.14740/jocmr2293w |url=}}</ref>. | * [[Aortic]] elasticity indices are impaired in patients with [[beta-thalassemia major]], and these parameters may be used to predict [[cardiovascular]] complications in asymptomatic patients<ref name="pmid26346439">{{cite journal |vauthors=Sahin C, Basaran O, Altun I, Akin F, Topal Y, Topal H, Biteker M, Azik MF |title=Assessment of Myocardial Performance Index and Aortic Elasticity in Patients With Beta-Thalassemia Major |journal=J Clin Med Res |volume=7 |issue=10 |pages=795–801 |date=October 2015 |pmid=26346439 |pmc=4554220 |doi=10.14740/jocmr2293w |url=}}</ref>. | ||
==References== | ==References== | ||
Revision as of 08:10, 25 August 2023
|
Beta-thalassemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Beta-thalassemia natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Beta-thalassemia natural history, complications and prognosis |
|
FDA on Beta-thalassemia natural history, complications and prognosis |
|
CDC on Beta-thalassemia natural history, complications and prognosis |
|
Beta-thalassemia natural history, complications and prognosis in the news |
|
Blogs on Beta-thalassemia natural history, complications and prognosis |
|
Risk calculators and risk factors for Beta-thalassemia natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Hadipour, M.D.[2]
Overview
Without regular blood transfusions, affected individuals by major beta-thalassemia typically develop severe anemia and other complications such as pulmonary hypertension, right heart failure, iron overload, infections early in life, while beta-thalassemia intermedia patients would have a variable clinical course, complications, and prognosis. Beta-thalassemia minor subjects would not have significant symptoms, while in some cases might have an increased risk for iron deficiency anemia. Iron overload complications happen in transfusion-dependent thalassemia.
Natural history
- Untreated beta-thalassemia can result in significant morbidity, mortality, and diminished quality of life. Patients with non-transfusion-dependent beta-thalassemia (NTD) can develop a wide range of complications in critical organ systems due to ineffective erythropoiesis, hemolysis, and primary iron overload. NTD patients can progress to transfusion-dependent beta-thalassemia (TD) later in life, which further exacerbates the risk of complications and iron overload[1].
- Untreated thalassemia major patients are at a high risk of developing pulmonary hypertension and right heart failure. The prevalence of these conditions in beta-thalassemia patients depends on the severity of the disease and the adequacy of treatment. Thalassemia major patients who do not receive treatment almost universally develop pulmonary hypertension. On the other hand, thalassemia intermedia patients are more likely to develop pulmonary hypertension compared to treated thalassemia major patients[2].
- Untreated beta-thalassemia major patients may also experience irreversible bone and organ damage due to iron overload[3].
Complications
Beta-thalassemia is associated with complications such as:
- Hemolytic anemia, chronic microcytic hypochromic anemia
- Iron overload due to chronic hemolysis and transfusion
- Irreversible bone and organ damage secondary to iron overload[3].
- Oxidative stress, which is mainly caused by tissue injury due to the overproduction of free radicals resulting from secondary iron overload[4].
- Infections (hepatitis B, hepatitis C, HIV) due to contaminated blood transfusion[5].
Prognosis
The prognosis of beta-thalassemia depends on the severity of the disease and the presence of complications.
- Beta-thalassemia major: Without treatment, individuals with thalassemia major may experience growth retardation, pallor, jaundice, poor musculature, hepatosplenomegaly, leg ulcers, and skeletal changes. Regular transfusion therapy can lead to iron overload-related complications, including endocrine complications, dilated cardiomyopathy, liver fibrosis, and cirrhosis. Cardiac disease caused by myocardial injury is the most important life-limiting complication of iron overload in beta-thalassemia.
- Beta-thalassemia intermedia: present later in life with moderate anemia and do not require regular transfusions. However, they may experience complications such as hypertrophy of erythroid marrow with medullary and extramedullary hematopoiesis, gallstones, painful leg ulcers, and increased predisposition to thrombosis.
- Beta-thalassemia minor: clinically asymptomatic, but some individuals may have moderate anemia[6].
The prognosis of beta-thalassemia can also be influenced by cardiovascular involvement.
- Parenchymal injury secondary to myocardial iron deposition and immune-inflammatory processes are known to be primary reasons for cardiovascular disorders in patients with thalassemia.
- Early abnormalities in ventricular myocardium can occur in patients with beta-thalassemia, even in those receiving effective chelation therapies.
- Aortic elasticity indices are impaired in patients with beta-thalassemia major, and these parameters may be used to predict cardiovascular complications in asymptomatic patients[7].
References
- ↑ Tang CH, Furnback W, Wang B, Tang J, Tang D, Lu MY, Huang VW, Musallam KM (October 2021). "Relationship between transfusion burden, healthcare resource utilization, and complications in patients with beta-thalassemia in Taiwan: A real-world analysis". Transfusion. 61 (10): 2906–2917. doi:10.1111/trf.16636. PMC 9291481 Check
|pmc=value (help). PMID 34505291 Check|pmid=value (help). Vancouver style error: initials (help) - ↑ Bloomfield GS, Lagat DK, Akwanalo OC, Carter EJ, Lugogo N, Vedanthan R, Velazquez EJ, Kimaiyo S, Sherman CB (September 2012). "Waiting to inhale: An exploratory review of conditions that may predispose to pulmonary hypertension and right heart failure in persons exposed to household air pollution in low- and middle-income countries". Glob Heart. 7 (3): 249–259. doi:10.1016/j.gheart.2012.06.015. PMC 3653331. PMID 23687634.
- ↑ 3.0 3.1 Bender MA, Hulihan M, Dorley MC, Aguinaga M, Ojodu J, Yusuf C (December 2021). "Newborn Screening Practices for Beta-Thalassemia in the United States". Int J Neonatal Screen. 7 (4). doi:10.3390/ijns7040083. PMC 8703506 Check
|pmc=value (help). PMID 34940053 Check|pmid=value (help). Vancouver style error: initials (help) - ↑ Shazia Q, Mohammad ZH, Rahman T, Shekhar HU (2012). "Correlation of oxidative stress with serum trace element levels and antioxidant enzyme status in Beta thalassemia major patients: a review of the literature". Anemia. 2012: 270923. doi:10.1155/2012/270923. PMC 3357501. PMID 22645668.
- ↑ Manisha S, Sanjeev K, Seema N, Dilip C, Rashmi D (2015). "A Cross-Sectional Study on Burden of Hepatitis C, Hepatitis B, HIV and Syphilis in Multi-Transfused Thalassemia Major Patients Reporting to a Government Hospital of Central India". Indian J Hematol Blood Transfus. 31 (3): 367–73. doi:10.1007/s12288-014-0462-5. PMC 4465515. PMID 26085723.
- ↑ Galanello R, Origa R (May 2010). "Beta-thalassemia". Orphanet J Rare Dis. 5: 11. doi:10.1186/1750-1172-5-11. PMC 2893117. PMID 20492708.
- ↑ Sahin C, Basaran O, Altun I, Akin F, Topal Y, Topal H, Biteker M, Azik MF (October 2015). "Assessment of Myocardial Performance Index and Aortic Elasticity in Patients With Beta-Thalassemia Major". J Clin Med Res. 7 (10): 795–801. doi:10.14740/jocmr2293w. PMC 4554220. PMID 26346439.